Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Nektar Therapeutics (NKTR)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 6,081,453
  • Shares Outstanding, K 174,104
  • Annual Sales, $ 1,193 M
  • Annual Income, $ 681,310 K
  • 60-Month Beta 3.09
  • Price/Sales 5.18
  • Price/Cash Flow 8.88
  • Price/Book 3.58

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/19
See More
  • Average Estimate -0.72
  • Number of Estimates 6
  • High Estimate -0.63
  • Low Estimate -0.82
  • Prior Year -0.60
  • Growth Rate Est. (year over year) -20.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
34.30 +0.55%
on 03/19/19
44.06 -21.72%
on 02/20/19
-8.32 (-19.43%)
since 02/19/19
3-Month
29.22 +18.04%
on 12/24/18
47.11 -26.79%
on 02/11/19
+0.23 (+0.67%)
since 12/19/18
52-Week
29.22 +18.04%
on 12/24/18
109.09 -68.38%
on 03/21/18
-70.52 (-67.16%)
since 03/19/18

Most Recent Stories

More News
Nektar Therapeut Falls 1.32% on Heavy Volume: Watch For Potential Rebound

Nektar Therapeut (NASDAQ:NKTR) traded in a range yesterday that spanned from a low of $35.06 to a high of $36.66. Yesterday, the shares fell 1.3%, which took the trading range below the 3-day low of...

NKTR : 34.47 (-1.32%)
Top 5 Companies in the Pharmaceuticals Industry with the Best Relative Performance (AERI , NKTR , PBH , PCRX , MDCO )

Below are the top five companies in the Pharmaceuticals industry as measured by relative performance. This analysis was compiled based on yesterday's trading activity as we search for stocks that have...

AERI : 45.72 (-2.91%)
PBH : 28.83 (+1.34%)
NKTR : 34.47 (-1.32%)
Best Relative Performance in the Pharmaceuticals Industry Detected in Shares of Therapeuticsmd (TXMD , MDCO , NKTR , MNK , ZTS )

Below are the top five companies in the Pharmaceuticals industry as measured by relative performance. This analysis was compiled based on yesterday's trading activity as we search for stocks that have...

MDCO : 26.59 (-2.03%)
NKTR : 34.47 (-1.32%)
Watch for Nektar Therapeut to Potentially Pullback After Gaining 2.91% Yesterday

Nektar Therapeut (NASDAQ:NKTR) traded in a range yesterday that spanned from a low of $34.94 to a high of $37.24. Yesterday, the shares gained 2.9%, which took the trading range above the 3-day high...

NKTR : 34.47 (-1.32%)
Stock Market News For Mar 7, 2019

Benchmarks ended in the red on Wednesday after a slew of weak economic reports weighed on the markets.

HCA : 137.22 (+1.83%)
WBA : 64.06 (+1.55%)
ANF : 26.13 (-0.61%)
NKTR : 34.47 (-1.32%)
Nektar Therapeutics to Webcast Presentation at the Cowen and Company 39th Annual Health Care Conference

Nektar Therapeutics (Nasdaq: NKTR) today announced that its Chief Scientific Officer, Jonathan Zalevsky, Ph.D., is scheduled to present at the Cowen and Company 39th Annual Health Care Conference on Tuesday,...

NKTR : 34.47 (-1.32%)
Detailed Research: Economic Perspectives on Canopy Growth, Aimmune Therapeutics, Nektar Therapeutics, Workday, Workiva, and MAG Silver -- What Drives Growth in Today's Competitive Landscape

In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders, and shareholders of Canopy Growth Corporation (NYSE:CGC),...

AIMT : 21.82 (-2.59%)
MAG : 10.88 (+0.83%)
WK : 49.01 (+1.30%)
WDAY : 191.05 (+1.89%)
CGC : 45.93 (+0.53%)
NKTR : 34.47 (-1.32%)
Biotechnology Companies see Rising Demand for new Therapies

The biotechnology market is one of the biggest industries in the world. However, despite being the largest sector globally, there are still various segments that haven't been tapped into, presenting opportunities...

QGEN : 40.00 (+0.78%)
SGEN : 73.19 (-0.35%)
PBIO : 3.1900 (-2.45%)
GE : 10.26 (+0.59%)
NKTR : 34.47 (-1.32%)
BioXcel Therapeutics Announces Addition of Merck KGaA, Darmstadt, Germany, and Pfizer to Clinical Collaboration with Nektar for Development of Triple-combination Therapy in Pancreatic Cancer

Clinical partnership to evaluate triple combination of BioXcel Therapeutics' BXCL701, Nektar's NKTR-214 and avelumab (Merck KGaA, Darmstadt, Germany and Pfizer) in pancreatic cancer

BTAI : 10.29 (-0.39%)
PFE : 42.26 (+1.08%)
MKKGY : 22.7550 (+1.20%)
NKTR : 34.47 (-1.32%)
Nektar Therapeutics Presents Preliminary Immune Activation, Safety and Clinical Activity Data from the Ongoing Dose-Escalation Stage of the REVEAL Study at 2019 ASCO-SITC Meeting

Nektar Therapeutics (Nasdaq: NKTR) today announced early results from the ongoing dose-escalation stage of the first-in-human REVEAL Phase 1/2 clinical study evaluating the safety and efficacy of NKTR-262,...

NKTR : 34.47 (-1.32%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Sell with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Average.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Trade NKTR with:

Business Summary

Nektar Therapeutics is a clinical-stage biopharmaceutical company developing a pipeline of drug candidates that utilize its PEGylation and polymer conjugate technology platforms, which are designed to meet unmet medical needs and improve the benefits of drugs for patients. Its product pipeline consists...

See More

Key Turning Points

2nd Resistance Point 36.67
1st Resistance Point 35.80
Last Price 34.47
1st Support Level 34.30
2nd Support Level 33.67

See More

52-Week High 109.09
Fibonacci 61.8% 78.58
Fibonacci 50% 69.15
Fibonacci 38.2% 59.73
Last Price 34.47
52-Week Low 29.22

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar